Preface |
|
xi | |
General Introduction |
|
1 | (6) |
|
Bench-Top and Primary Bioassay Screening |
|
|
7 | (100) |
|
|
9 | (5) |
|
Brine-shrimp lethality assay |
|
|
9 | (1) |
|
Brine-shrimp microwell cytotoxicity assay |
|
|
10 | (2) |
|
Crown gall tumor inhibition assay (potato disc antitumor assay) |
|
|
12 | (2) |
|
|
14 | (1) |
|
|
14 | (11) |
|
|
16 | (1) |
|
|
16 | (1) |
|
|
17 | (1) |
|
|
18 | (1) |
|
Direct bioautobiography method |
|
|
19 | (3) |
|
|
22 | (1) |
|
|
22 | (2) |
|
Direct bioautobiography method |
|
|
24 | (1) |
|
Antiviral and Anticancer Assays |
|
|
25 | (14) |
|
|
25 | (2) |
|
|
27 | (1) |
|
In vitro anticancer screening |
|
|
28 | (9) |
|
|
37 | (2) |
|
|
39 | (2) |
|
Antimitotic assay using sea urchin eggs |
|
|
39 | (2) |
|
|
41 | (7) |
|
SOS chromtest for genotoxicity |
|
|
41 | (3) |
|
Ames test for detecting carcinogens and mutagens |
|
|
44 | (3) |
|
|
47 | (1) |
|
Assays for Control of Tropical Diseases |
|
|
48 | (17) |
|
|
48 | (1) |
|
96 well plate in vitro schizonticidal assay |
|
|
49 | (1) |
|
Suppressive test of blood schizonticidal action (Peter's test) |
|
|
50 | (1) |
|
Rane test of blood schizonticidal activity |
|
|
51 | (1) |
|
|
51 | (1) |
|
|
52 | (1) |
|
|
53 | (1) |
|
|
54 | (5) |
|
|
59 | (1) |
|
|
60 | (1) |
|
In vitro Leishmanicidal assay (promastigotes) |
|
|
60 | (2) |
|
In vitro Leishmanicidal assay (amastigotes) |
|
|
62 | (2) |
|
Leishmanicidal activity in vivo |
|
|
64 | (1) |
|
|
65 | (9) |
|
Lemna minor for phytotoxicity and growth-stimulating assay |
|
|
65 | (2) |
|
Contact toxicity insecticidal assay |
|
|
67 | (1) |
|
Insect antifeedant assays |
|
|
68 | (1) |
|
|
68 | (1) |
|
Artificial diet feeding bioassay |
|
|
69 | (3) |
|
|
72 | (2) |
|
|
74 | (8) |
|
Antihepatotoxic activity using carbon tetrachloride-induced cytotoxicity |
|
|
74 | (2) |
|
In vivo hepatoprotective assay |
|
|
76 | (2) |
|
Antihepatotoxic activity using galactosamine induced cytotoxicity |
|
|
78 | (4) |
|
Hypoglycemic/Antidiabetic Activity Assays |
|
|
82 | (5) |
|
Antidiabetic activity assay on normal and alloxan-diabetic rabbits |
|
|
82 | (2) |
|
Antidiabetic activity assay (GOD-PAP method) |
|
|
84 | (1) |
|
Hypoglycemic activity assay |
|
|
85 | (2) |
|
|
87 | (1) |
|
Anthelmintic Activity Assays |
|
|
88 | (2) |
|
In vitro anthelmintic assay |
|
|
88 | (2) |
|
In vivo anthelmintic assay |
|
|
90 | (1) |
|
Antifertility/Anti-implantation Assays |
|
|
90 | (2) |
|
|
90 | (1) |
|
Anti-implantation activity |
|
|
91 | (1) |
|
In Vitro Assay for Platelet Aggregation |
|
|
92 | (2) |
|
|
94 | (1) |
|
|
94 | (1) |
|
|
95 | (1) |
|
|
95 | (1) |
|
Antiepileptic (Anticonvulsant) Assay |
|
|
96 | (4) |
|
|
97 | (3) |
|
|
100 | (1) |
|
|
100 | (1) |
|
|
100 | (1) |
|
Gastroprotective/Antiulcer Assays |
|
|
101 | (2) |
|
|
101 | (1) |
|
|
102 | (1) |
|
|
103 | (1) |
|
|
103 | (3) |
|
|
103 | (3) |
|
|
106 | (1) |
|
High-Throughput Screening |
|
|
107 | (112) |
|
|
109 | (5) |
|
Characteristics of an ideal screening assay for screening natural product extracts |
|
|
109 | (1) |
|
Biochemical or cell based assays |
|
|
110 | (1) |
|
|
110 | (1) |
|
|
111 | (1) |
|
Assay signal-to-noise ratio |
|
|
112 | (1) |
|
|
112 | (1) |
|
|
113 | (1) |
|
|
113 | (1) |
|
Screening source material compatibility |
|
|
113 | (1) |
|
|
114 | (38) |
|
|
114 | (1) |
|
Considerations for development of enzyme assays |
|
|
114 | (1) |
|
Selection of enzyme source |
|
|
115 | (1) |
|
Selection of enzyme concentration |
|
|
116 | (1) |
|
Selection of substrate and substrate concentration |
|
|
116 | (5) |
|
Selection of cofactor concentrations |
|
|
121 | (1) |
|
Selection of assay endpoint |
|
|
122 | (1) |
|
|
122 | (1) |
|
Selection of assay temperature |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
124 | (1) |
|
|
125 | (1) |
|
Noncompetitive inhibition |
|
|
125 | (1) |
|
Development of a high throughput enzyme assay for natural product screening: an example |
|
|
126 | (7) |
|
Some common in vitro enzyme-based bioassays |
|
|
133 | (1) |
|
Protease inhibition assays |
|
|
133 | (4) |
|
Tyrosinase inhibition assay |
|
|
137 | (2) |
|
Hyaluronidase inhibition assay |
|
|
139 | (3) |
|
Acetylcholinesterase inhibition assay |
|
|
142 | (1) |
|
|
143 | (2) |
|
β-Lactamase inhibition assay |
|
|
145 | (1) |
|
|
146 | (2) |
|
5-Lipoxygenase inhibition assay |
|
|
148 | (1) |
|
|
149 | (3) |
|
Cell-based Receptor Functional Assays |
|
|
152 | (27) |
|
|
152 | (1) |
|
Utility of receptor functional assays |
|
|
152 | (1) |
|
Functional assays for G-protein coupled receptors |
|
|
152 | (1) |
|
Gs and Gi coupled receptor signal transduction pathways |
|
|
152 | (3) |
|
High throughput functional assays for Gs and Gi coupled receptors |
|
|
155 | (1) |
|
Common cell-based receptor functional assays |
|
|
155 | (1) |
|
|
155 | (1) |
|
|
156 | (1) |
|
|
157 | (3) |
|
cAMP response element reporter gene assay |
|
|
160 | (1) |
|
Gq-coupled receptor signal transduction pathways |
|
|
161 | (1) |
|
|
161 | (3) |
|
High throughput assays for Gq-coupled receptors |
|
|
164 | (1) |
|
High throughput functional assays for ligand-gated ion channels |
|
|
165 | (2) |
|
Receptor protein tyrosine kinase functional assays |
|
|
167 | (1) |
|
|
167 | (1) |
|
RPTK-associated signal transduction pathways |
|
|
167 | (2) |
|
High throughput functional assays for RPTK'S |
|
|
169 | (1) |
|
Intracellular calcium assay |
|
|
169 | (1) |
|
|
170 | (3) |
|
Cytokine receptor functional assays |
|
|
173 | (1) |
|
Cytokine receptor signal transduction pathways |
|
|
173 | (1) |
|
Functional assays for cytokine receptors |
|
|
173 | (1) |
|
Mixed receptor functional assay |
|
|
174 | (1) |
|
Melanophore functional receptor assay technology |
|
|
174 | (4) |
|
Receptor selection and amplification functional receptor assay technology |
|
|
178 | (1) |
|
Radioligand Binding Assays |
|
|
179 | (26) |
|
|
179 | (1) |
|
Important considerations for developing radioligand binding assays |
|
|
180 | (1) |
|
Receptor source and assay concentration |
|
|
180 | (1) |
|
Nonrecombinant human cell lines |
|
|
180 | (1) |
|
Membrane preparations from nonrecombinant cells and tissues |
|
|
181 | (1) |
|
Recombinant receptor containing cells or membranes |
|
|
181 | (1) |
|
Selection of radioligand and assay concentration |
|
|
182 | (2) |
|
Selection of assay incubation conditions |
|
|
184 | (1) |
|
Selection of assay buffer |
|
|
184 | (1) |
|
Selection of assay volume |
|
|
184 | (1) |
|
Selection of a methodology for separation of free and bound radioligand |
|
|
185 | (1) |
|
Steps in developing and validating radioligand binding |
|
|
185 | (1) |
|
Steps in developing and validating radioligand binding assays |
|
|
185 | (1) |
|
Cell membrane linearity evaluation |
|
|
186 | (1) |
|
Association and dissociation time courses |
|
|
187 | (5) |
|
Saturation isotherm evaluation |
|
|
192 | (2) |
|
|
194 | (4) |
|
Alternative radioligand binding assays |
|
|
198 | (1) |
|
|
198 | (2) |
|
Scintillation proximity assays |
|
|
200 | (1) |
|
|
201 | (2) |
|
Fluorescence based receptor binding |
|
|
203 | (1) |
|
Time resolved fluorescence |
|
|
203 | (1) |
|
Fluorescence polarization |
|
|
203 | (2) |
|
|
205 | (14) |
|
|
219 | |